世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など...市場調査レポートについてご紹介

【英文タイトル】Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms

3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024

4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024

5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024

6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology

7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes

8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers

9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024


【レポート販売概要】

■ タイトル:世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など
■ 英文:Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
■ 発行日:2014年6月
■ 調査会社:visiongain
■ 商品コード:VISG409052
■ 調査対象地域:グローバル
  • 新生血管緑内障(Neovascular Glaucoma):世界の治験レビュー(2015年上半期版)
    Neovascular Glaucoma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Neovascular Glaucoma Global Clinical Trials Review, H1, 2015" provides data on the Neovascular Glaucoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neovascular Glaucoma. It includes an overview of the trial numbers and their r …
  • 世界の半導体市場2015-2020
    The Global Semiconductor Market 2015- 2020 is GMR Data’s latest Tech sector report. This report forecasts revenues for key services across key geographies. The global semiconductor market is forecast, by GMR Data, to reach $332bn across 2015, representing a 3.4% growth in comparison to $316bn in 2014. GMR Data forecasts that the market will grow at a 5-yr CAGR of 2.9% over 2015 to 2020, with the m …
  • 骨髄異形成症候群(MDS)治療薬の世界市場2015-2019
    About Myelodysplastic Syndrome Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with …
  • ホルモノネチンの世界市場
    Formononetin (CAS 485-72-3) Market Research Report 2014 presents comprehensive data on formononetin markets globally and regionally (Europe, Asia, North America etc.) The report includes formononetin description, covers its application areas and related patterns. It overviews formononetin market, names formononetin producers and indicates its suppliers. Besides, the report provides formononetin pr …
  • 脳神経外科用装置の世界市場予測(~2024年)
    “The neurosurgery devices market is projected to grow at a CAGR of 13.0% during the forecast period.”The neurosurgery devices market is projected to reach USD 13.5 billion by 2024 from USD 7.3 billion in 2019, at a CAGR of 13.0% during the forecast period. Growth in this market can be attributed to the rising prevalence of neurological disorders, efforts to develop the application base for neuromo …
  • 薬局オートメーションの世界市場予測(~2022年):薬剤分注装置、包装・ラベル装置、計数装置、保管装置
    The pharmacy automation market is expected to grow at a lucrative CAGR of 8.2% from 2017 to 2022, to reach USD 5.38 billion by 2022 from USD 3.63 billion in 2017. The growth in pharmacy automation market is primarily due to the increased focus on reducing medication errors, increased burden on pharmacies due to rising geriatric population, rapid decentralization of pharmacies, and rising labor cos …
  • 非結晶性PETの世界市場予測
    The global amorphous PET market is projected to reach USD 36.40 Billion by 2020, at a CAGR of 7.5% from 2015 to 2020. The bottles application segment is projected to hold the largest share in the global market in 2015, owing to increased demand of amorphous PET for the packaging of beverages. The report covers the global market across major geographical regions, which include Asia-Pacific, Europe, …
  • 乳製品検査の世界市場予測(~2022年):安全(病原体、混物、農薬)、品質、技術、製品
    “The dairy testing market is projected to grow at a CAGR of 7.4%.”The dairy testing market is projected to reach USD 5.90 billion by 2022 from USD 4.13 billion in 2017, at a CAGR of 7.4%. The market is driven by an increase in the outbreak of foodborne illnesses, globalization of dairy trade, and stringent safety and quality regulations for food. Lack of coordination between market stakeholders an …
  • ジャム/ゼリー/保存食の世界市場2016-2020
    About Jams, Jellies, and Preserves The use of jams, jellies, and preserves is increasing in salads, cookies, pizzas, sandwiches, and smoothies as customers are willing to expand their taste pallet. In the new era, where healthy eating is becoming the prime motive of many consumers, the vendors increase their sales by focusing on products that are both indulgent, have high fruit content, and/or are …
  • 航空機シート用アクチュエータの世界市場:リニアアクチュエータ、回転式アクチュエータ、電気機械式アクチュエータ
    The seat actuation systems market is projected to grow at a CAGR of 13.02% during the forecast period (2015-2020). This report includes the financial analysis of key market players, historical market analysis, technology trends, market environment analysis, industry overview, which includes supply chain analysis, value chain analysis, and demand model for the market. The report also includes the k …
  • Pan Orient Energy Corp.:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013
    Pan Orient Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Pan Orient Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential so …
  • はしごの世界市場2018-2022
    About Ladder A ladder is a vertical or inclined set of rungs or steps. Two types of ladders are available in the market— rigid ladders and flexible ladders. The market includes the value sales of ladders used for domestic, commercial, and industrial applications. Technavio’s analysts forecast the global ladder market to grow at a CAGR of 5.44% during the period 2018-2022. Covered in this report Th …
  • オンライン言語学習の米国市場2017-2021
    About Online Language Learning The education market in the US has seen the emergence of new pedagogical techniques. Changes in the education policy along with the implementation of Common Core State Standards have necessitated educators in the US to enroll in professional development courses to acquire information and communication technology (ICT) and language skills along with techniques to succ …
  • 世界のビデオサーバ市場動向(2012-2016)
    TechNavio's analysts forecast the Global Video Server market to grow at a CAGR of 11.46 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for HD video content. The Global Video Server market has also been witnessing the advances in server technologies. However, the lack of broadband infrastructure in certain regions could pose a c …
  • 先進創傷ケアの世界市場:ドレッシング、治療デバイス、アクティブ創傷ケア
    Wound care management is a growing field that has been witnessing a number of technological advancements lately. There are various products available in the market, which have made the treatment of wounds easier. Companies operating in the global advanced wound care market are focusing on incorporating advanced and innovative features in their products to differentiate them from other products ava …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。